Immunizations could be administered within minutes where and when a disease is breaking out.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
University of Washington engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.
“We’re really excited about this technology because it makes it possible to produce a vaccine on the spot. For instance, a field doctor could see the beginnings of an epidemic, make vaccine doses right away, and blanket vaccinate the entire population in the affected area to prevent the spread of an epidemic,” said François Baneyx, a UW professor of chemical engineering and lead author of a recent paper published online in the journal Nanomedicine.
The research was funded by a Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation and the National Institutes of Health.
In typical vaccines, weakened pathogens or proteins found on the surface of microbes and viruses are injected into the body along with compounds called adjuvants to prepare a person’s immune system to fight a particular disease. But standard formulations don’t always work, and the field is seeking ways to manufacture vaccines quicker, cheaper and tailored to specific infectious agents, Baneyx said.
The UW team injected mice with nanoparticles synthesized using an engineered protein that both mimics the effect of an infection and binds to calcium phosphate, the inorganic compound found in teeth and bones. After eight months, mice that contracted the disease made threefold the number of protective “killer” T-cells – a sign of a long-lasting immune response – compared with mice that had received the protein but no calcium phosphate nanoparticles.
The nanoparticles appear to work by ferrying the protein to the lymph nodes where they have a higher chance of meeting dendritic cells, a type of immune cell that is scarce in the skin and muscles, but plays a key role in activating strong immune responses.
In a real-life scenario, genetically engineered proteins based on those displayed at the surface of pathogens would be freeze-dried or dehydrated and mixed with water, calcium and phosphate to make the nanoparticles. This should work with many different diseases and be especially useful for viral infections that are hard to vaccinate against, Baneyx said.
He cautioned, however, that it has only been proven in mice, and the development of vaccines using this method hasn’t begun for humans.
The Latest on: On-demand vaccines
[google_news title=”” keyword=”On-demand vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: On-demand vaccines
- Pandemic treaty will give WHO power to demand 20pc of British vaccineson April 28, 2024 at 10:13 am
The World Health Organisation (WHO) will have the power to legally demand that Britain hands over 20 per cent of its vaccines and drugs in a pandemic under a treaty due to be ratified next month. In ...
- Negativity About Vaccination On Twitter Increases After COVID-19 Vaccines Become Availableon April 27, 2024 at 4:12 pm
For instance, one negative tweet read:“The EU Commission should immediately terminate contracts for new doses of fake #vaccines against #COVID19 and demand the return of the €2.5bn paid so far.
- Demand for a shingles vaccine is high in Canberra, but some say they are struggling to access iton April 25, 2024 at 5:24 pm
Paul Dowden has had shingles three times, and says it is ''the worst pain" he's experienced. He's urging people to get vaccinated, but as demand "far exceeds" supply in the ACT, that is easier said ...
- A Vaccine to Fight Antibiotic Resistanceon April 25, 2024 at 2:25 pm
MSU, Harvard Medical School team up to expand vaccine science’s role in the fight against MRSA and other infections ...
- Demand for the cholera vaccine is soaring – this company might have a solutionon April 25, 2024 at 9:02 am
In the global race to provide enough vaccines to tackle the ever-growing threat posed by cholera, one company is leading the field.
- Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Resultson April 25, 2024 at 8:10 am
Key TakeawaysMerck beat earnings and revenue estimates on strong sales of its Keytruda cancer medicine and Gardasil HPV vaccine.The pharmaceutical giant explained that results would have been even ...
- Vaccines are a glimmer of hope against malaria, but the battle has only just begunon April 25, 2024 at 6:10 am
By the time you reach the end of this article, three children will have died from malaria – a disease that casts a dark shadow over nearly half of the world’s population, claiming victims ...
- Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Programon April 25, 2024 at 5:24 am
Under the terms of the contract, Applied DNA will supply Linea™ DNA IVT templates to HDT Bio for use in conjunction with its LION™ formulated repRNA (self-replicating RNA) vaccination platform. The ...
- Global Pneumococcal Vaccines Market to Witness Steady Growth, Projected to surpass US$ 13.3 Billion by 2033on April 24, 2024 at 7:48 pm
Pneumococcal Vaccines Market is expected to surpass US$ 13.3 Billion by 2033 to advance at a CAGR of 4.1% from 2023 to 2033.
- Vaccines save at least 154 million lives in 50 years: WHOon April 24, 2024 at 6:32 am
Global immunisation efforts have saved at least 154 million lives in the past 50 years, the World Health Organization said Wednesday, adding that most of those to benefit were infants.
via Bing News